Trials / Recruiting
RecruitingNCT06348576
Phase III Study to Evaluate the Efficacy and Safety of AD-209
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Detailed description
Condition or disease : hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-209 | PO, Once daily(QD), 8weeks |
| DRUG | AD-2091 | PO, Once daily(QD), 8weeks |
| DRUG | AD-209 Placebo | PO, Once daily(QD), 8weeks |
| DRUG | AD-2091 Placebo | PO, Once daily(QD), 8weeks |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2024-04-04
- Last updated
- 2024-05-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06348576. Inclusion in this directory is not an endorsement.